Reviewer’s report

Title: Risk Factors Affecting Prognosis in Metachronous Liver Metastases from WHO Classification G1 and G2 Gastroenteropancreatic Neuroendocrine Tumors after Initial R0 Surgical Resection

Version: 0 Date: 30 Jan 2019

Reviewer: Ming Lu

Reviewer's report:

This study retrospectively analyzed the clinico-pathology and prognosis of 108 patients with GEP-NET metachronous liver metastases from 2003 to 2014. It is suggested that increased Ki67 index of liver metastases compared with the primary tumors is an important prognostic factor. The phenomenon is relatively common in tumors originated from gastrointestinal tract. The author proposed a prognostic risk model using multi-factor analysis, which was instructive for clinical practice. It's noted that the time span of the study was relatively long (2003-2014), during which the treatment modalities had changed over time. More novel strategies have been approved in the disease, including somatostatin analogues, everolimus and other target therapy. Such changes also exerted impact on the prognosis. Did the author take these factors into consideration?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal